AQR Capital Management - BRAINSTORM CELL THERAPEUTICS ownership

BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 59 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q3 2023. The put-call ratio across all filers is 0.29 and the average weighting 0.0%.

Quarter-by-quarter ownership
AQR Capital Management ownership history of BRAINSTORM CELL THERAPEUTICS
ValueSharesWeighting
Q4 2020$89,000
-74.4%
19,619
-4.3%
0.00%
-100.0%
Q3 2020$347,00020,5030.00%
Other shareholders
BRAINSTORM CELL THERAPEUTICS shareholders Q3 2023
NameSharesValueWeighting ↓
Weaver Consulting Group 130,000$437,0000.21%
Ikarian Capital, LLC 304,161$1,022,0000.13%
ABNER HERRMAN & BROCK LLC 265,000$890,0000.12%
S.C. Financial Services, Inc. 15,285$51,0000.06%
JMAC ENTERPRISES LLC 45,430$153,0000.04%
CFO4Life Group, LLC 12,000$40,0000.01%
OSAIC HOLDINGS, INC. 10,839$1,329,0000.00%
INSTITUTIONAL & FAMILY ASSET MANAGEMENT, LLC 3,000$10,0000.00%
BOOTHBAY FUND MANAGEMENT, LLC 29,186$98,0000.00%
RAYMOND JAMES & ASSOCIATES 190,403$640,0000.00%
View complete list of BRAINSTORM CELL THERAPEUTICS shareholders